PMID- 20507312
OWN - NLM
STAT- MEDLINE
DCOM- 20100901
LR  - 20220408
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 150
IP  - 2
DP  - 2010 Jul
TI  - All trans retinoic acid nanodisks enhance retinoic acid receptor mediated 
      apoptosis and cell cycle arrest in mantle cell lymphoma.
PG  - 158-69
LID - 10.1111/j.1365-2141.2010.08209.x [doi]
AB  - Mantle cell lymphoma (MCL) is characterized by translocation t(11;14)(q13;q32), 
      aggressive clinical behaviour, and poor patient outcomes following conventional 
      chemotherapy. New treatment approaches are needed that target novel biological 
      pathways. All trans retinoic acid (ATRA) is a key retinoid that acts through 
      nuclear receptors that function as ligand-inducible transcription factors. The 
      present study evaluated cell killing effects of ATRA-enriched nanoscale delivery 
      particles, termed nanodisks (ND), on MCL cell lines. Results show that ATRA-ND 
      induced cell death more effectively than naked ATRA (dimethyl sulphoxide) or 
      empty ND. ATRA-ND induced reactive oxygen species (ROS) generation to a greater 
      extent than naked ATRA. The antioxidant, N-acetylcysteine, inhibited ATRA-ND 
      induced apoptosis. Compared to naked ATRA, ATRA-ND enhanced G1 growth arrest, 
      up-regulated p21and p27, and down regulated cyclin D1. At ATRA concentrations 
      that induced apoptosis, expression levels of retinoic acid receptor-alpha 
      (RARalpha) and retinoid X receptor-gamma (RXRgamma) were increased. Compared to 
      naked ATRA, ATRA-ND significantly stimulated transcriptional activity of RARA in 
      a model carcinoma cell line. Furthermore, the RAR antagonist, Ro 41-5253, 
      inhibited ATRA-ND induced ROS generation and prevented ATRA-ND induced cell 
      growth arrest and apoptosis. In summary, incorporation of ATRA into ND enhanced 
      the biological activity of this retinoid in cell culture models of MCL.
FAU - Singh, Amareshwar T K
AU  - Singh AT
AD  - Division of Haematology/Oncology, Department of Medicine, Northwestern University 
      Feinberg School of Medicine, Chicago, IL 60611, USA. a-singh@northwestern.edu
FAU - Evens, Andrew M
AU  - Evens AM
FAU - Anderson, Reilly J
AU  - Anderson RJ
FAU - Beckstead, Jennifer A
AU  - Beckstead JA
FAU - Sankar, Natesan
AU  - Sankar N
FAU - Sassano, Antonella
AU  - Sassano A
FAU - Bhalla, Savita
AU  - Bhalla S
FAU - Yang, Shuo
AU  - Yang S
FAU - Platanias, Leonidas C
AU  - Platanias LC
FAU - Forte, Trudy M
AU  - Forte TM
FAU - Ryan, Robert O
AU  - Ryan RO
FAU - Gordon, Leo I
AU  - Gordon LI
LA  - eng
GR  - R01 CA121192/CA/NCI NIH HHS/United States
GR  - R37 HL064159/HL/NHLBI NIH HHS/United States
GR  - R43 CA141904-01/CA/NCI NIH HHS/United States
GR  - R01 HL064159-12/HL/NHLBI NIH HHS/United States
GR  - 1R43CA141904/CA/NCI NIH HHS/United States
GR  - P30 CA060553/CA/NCI NIH HHS/United States
GR  - HL-64159/HL/NHLBI NIH HHS/United States
GR  - R01 HL064159/HL/NHLBI NIH HHS/United States
GR  - R43 CA141904/CA/NCI NIH HHS/United States
GR  - R01 CA121192-05/CA/NCI NIH HHS/United States
GR  - CA121192/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20100509
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzoates)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Chromans)
RN  - 0 (Guanine Nucleotide Exchange Factors)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RCC1 protein, human)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoid X Receptors)
RN  - 144092-31-9 (Ro 41-5253)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*pharmacology
MH  - Apoptosis/drug effects
MH  - Benzoates/pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Cycle Proteins/biosynthesis/drug effects
MH  - Chromans/pharmacology
MH  - Drug Delivery Systems
MH  - Drug Evaluation, Preclinical
MH  - Guanine Nucleotide Exchange Factors/biosynthesis/drug effects
MH  - Humans
MH  - Lymphoma, Mantle-Cell/metabolism/*pathology
MH  - Nanoparticles
MH  - Neoplasm Proteins/biosynthesis/drug effects
MH  - Nuclear Proteins/biosynthesis/drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Receptors, Retinoic Acid/antagonists & inhibitors/*drug effects/metabolism
MH  - Retinoid X Receptors/drug effects/metabolism
MH  - Transcription, Genetic/drug effects
MH  - Tretinoin/administration & dosage/*pharmacology
MH  - Tumor Cells, Cultured
PMC - PMC2907750
MID - NIHMS212465
COIS- Conflict-of-Interest Disclosure The authors declare no competing financial 
      interests.
EDAT- 2010/05/29 06:00
MHDA- 2010/09/02 06:00
PMCR- 2011/07/01
CRDT- 2010/05/29 06:00
PHST- 2010/05/29 06:00 [entrez]
PHST- 2010/05/29 06:00 [pubmed]
PHST- 2010/09/02 06:00 [medline]
PHST- 2011/07/01 00:00 [pmc-release]
AID - BJH8209 [pii]
AID - 10.1111/j.1365-2141.2010.08209.x [doi]
PST - ppublish
SO  - Br J Haematol. 2010 Jul;150(2):158-69. doi: 10.1111/j.1365-2141.2010.08209.x. 
      Epub 2010 May 9.